Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 3Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Carcinoma, Hepatocellular 28Carcinoma, Non-Small-Cell Lung 23Lung Neoplasms 17Biliary Tract Neoplasms 13Small Cell Lung Carcinoma 12Cholangiocarcinoma 12Triple Negative Breast Neoplasms 8Breast Neoplasms 8Neoplasms 6Neoplasm Metastasis 5Liver Neoplasms 5Urinary Bladder Neoplasms 4Stomach Neoplasms 4Carcinoma 4Pancreatic Neoplasms 3Non-Muscle Invasive Bladder Neoplasms 3Gallbladder Neoplasms 3Colorectal Neoplasms 3Adenocarcinoma Of Esophagus 3Pathologic Complete Response 2Ovarian Neoplasms 2Esophageal Neoplasms 2Endometrial Neoplasms 2Bile Duct Neoplasms 2Advanced Biliary Tract Cancer 2Adenocarcinoma of Lung 2Adenocarcinoma 2Vaccinia 1SCLC, Limited Stage 1Resectable Intrahepatic Cholangiocarcinoma 1

Interventions

Carboplatin 5Nivolumab 4pembrolizumab 3Pemetrexed 3Ipilimumab 3fludarabine 2atezolizumab 2Cyclophosphamide 2Cisplatin 2tremelimumab 1sotorasib 1osimertinib 1olaparib 1durvalumab 1Tumor Burden 1Thoracoscopy 1Tablets 1Saline Solution 1Quality of Life 1Observation 1Magnesium Sulfate 1Injections 1Influenza Vaccines 1Histocompatibility Testing 1Gemcitabine 1Fluorodeoxyglucose F18 1Exercise Therapy 1Combined Modality Therapy 1Cell- and Tissue-Based Therapy 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Mesothelioma × durvalumab × Clear all
NCT05932199 2025-09-25

Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma

Baylor College of Medicine

Phase 1/2 Recruiting
52 enrolled
Other solid neoplasmThoracic

Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡